Skip to main content
European Commission logo print header

Neurological evaluation with simple tools to track evolution and perform early detection of neurodegenerative issues

Objectif

To the date there is no accurate scale to quantitatively measure motor dysfunction in neurological movement disorders. Doctors heavily relay on the information provided by the patients themselves. Objective data concerning the patient’s actual movements or seizures during their ordinary day would be very valuable for the doctors. The current common scales are only semi-quantitative, subjective and non continuous. As consequence, one of the problems it implies is related to the reduction of sensitivity of clinical changes observed in clinical trials. In addition, there are no motor assessments that can be used to investigate the disease progression in pre-symptomatic subjects. In other words, today neurologists do not have a tool that allows them to know objectively if the patient has more or less shaking than last time. Movement disorders are comprised of a variety of conditions resulting in abnormalities in the motor system. These include such disorders as Parkinson's disease and other Parkinsonian syndromes, tremors, dystonia, tics , Tourette syndrome, Alzheimer's and Huntington's diseases. They can occur in all age groups from infancy to the elderly. In some cases, symptoms are restricted to problems in motor control while in others cases, cognitive and autonomic functions can be affected.
mememtum provides a measuring tool and monitors progress of neurological patients and helps in early detection of certain disorders. Using image analysis techniques, the phone camera, screen and sensors, mememtum analyses and quantifies the state of the patient from a neurological and movement disorder point of view.
Our product revolutionizes the way to measure neurological condition in a simple and accurate way:
• Allowing remote patient tracking and evaluation of the movement disorders and its evolution
• Performing early detection and evaluating the patient’s neurological condition/evolution.

Appel à propositions

H2020-SMEInst-2014-2015

Voir d’autres projets de cet appel

Sous appel

H2020-SMEINST-1-2014

Régime de financement

SME-1 - SME instrument phase 1

Coordinateur

TANIWA SOLUCIONES SL
Contribution nette de l'UE
€ 50 000,00
Adresse
Av Alcalde Conde de Mayalde,23 ,5A
28050 Madrid
Espagne

Voir sur la carte

PME

L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.

Oui
Région
Comunidad de Madrid Comunidad de Madrid Madrid
Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Liens
Coût total
€ 71 429,00